Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®
CINCINNATI, April 25, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced that Blue Water management will attend the American Urological Association (“AUA”) Annual Meeting 2023 in Chicago, IL from April 28th to May 1st, 2023, to promote its asset ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia (“BPH”).
Related news for (BWV)
- Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences
- Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
- Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
- Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
- Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company